PO-1936 Performances of a binary blood assay for predicting radiosensitivity

2021 ◽  
Vol 161 ◽  
pp. S1650-S1651
Author(s):  
S. Deneuve ◽  
C. Mirjolet ◽  
T. Bastogne ◽  
M. duclos ◽  
P. Retif ◽  
...  
Keyword(s):  
Blood Assay

Non-Thrombogenicity of Clean Glass Revealed by Native Whole Blood Assay in Bead Columns

1983 ◽  
Vol 50 (04) ◽  
pp. 814-820 ◽  
Author(s):  
J A Bergeron ◽  
J M DiNovo ◽  
A F Razzano ◽  
W J Dodds
Keyword(s):  
Whole Blood ◽  
Glass Bead ◽  
Factor Xii ◽  
Platelet Factor ◽  
Serotonin Content ◽  
Whole Blood Assay ◽  
Vascular Integrity ◽  
Blood Assay ◽  
Standard Contact ◽  
Recalcification Time

SummaryThe previously described native whole blood assay for materials in solution or suspension has been adapted to materials in a bead column configuration. These experiments showed that the glass itself accounts for little or none of the high blood-reactivity observed with conventional glass bead columns. Columns composed solely of soft glass that was “cleaned” by heat treatment (500-595° C 18 hr, electric oven) were benign toward flowing native whole blood for all variables measured (platelet count and platelet-free plasma [C14]-serotonin content, platelet factor 3 and factor XII activities, and recalcification time) with the standard contact protocol. In addition, the effluent successfully maintained perfusion of the isolated kidney, a measure of the ability of platelets to support vascular integrity. Prolonged (30 min) normothermic contact with titrated whole blood increased the subsequent reactivity of initially clean glass toward whole blood albeit to a level much less than that of conventional glass bead columns.

Whole Blood Assay: Thromboelastometry – Bleeding Management Algorithms

2021 ◽  
pp. 67-87
Author(s):  
Klaus Görlinger ◽  
James Iqbal ◽  
Daniel Dirkmann ◽  
Kenichi A. Tanaka
Keyword(s):  
Whole Blood ◽  
Whole Blood Assay ◽  
Bleeding Management ◽  
Blood Assay ◽  
Management Algorithms

scholarly journals Hepatitis C Infections with Cryoglobulinemia: Features and Symptoms

Doctor Ru ◽  
2021 ◽  
Vol 20 (4) ◽  
pp. 26-32
Author(s):  
S.P. Lukashik ◽  
◽  
I.A. Karpov ◽  
O.V. Krasko ◽  
◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Hepatic Cirrhosis ◽  
Hepatitis C Infection ◽  
Genotype 3 ◽  
Virus Genotype ◽  
Study Objective ◽  
Blood Assay ◽  
Study Results

Study Objective: To study the incidence of cryoglobulinemia (CGE) in chronic hepatitis C infection (hepatitis C infection) and to analyse the characteristics of chronic hepatitis C infection with CGE in Belarusian patients. Study Design: Open non-randomised observational study. Materials and Methods. The study included 773 patients with chronic hepatitis C infection (in Minsk). The patients had their anti-hepatitis C antibodies, chronic hepatitis C RNA and virus genotype measured; blood cryoglobulins identified; demographic and epidemiological data collected; and complete blood assay and biochemical blood assay performed. Study Results. 282 (36.5%) subjects had positive blood cryoglobulins test, while 491 (63.5%) patients had negative result. CGE and non-CGE groups had comparable sex, BMI and infection duration parameters. CGE patients had statistically more surgeries (р < 0.001), clinical syndromes (including asthenovegetative, arthralgic and dyspeptic syndromes, р < 0.001 in all cases), hepatic fibrosis F3 (р < 0.05), hepatic cirrhosis (р < 0.001), and extrahepatic diseases (EHDs); more often they had genotype 3 of hepatitis C infection (р < 0.05) and low replicative activity of the virus (р < 0.05). Conclusion. The incidence of CGE in the study population made 36.5%. CGE patients had more pronounced hepatic process chronization, frequenter EHDs, more genotype 3 cases, and lower replicative activity of the virus. Keywords: hepatitis С, hepatic cirrhosis, cryoglobulinemia, extrahepatic diseases.

scholarly journals Analysis of the dynamics of Staphylococcus aureus binding to white blood cells using whole blood assay and geno-to-pheno mapping

2020 ◽  
Vol 310 (3) ◽  
pp. 151411
Author(s):  
Daria Gaidar ◽  
Alice Jonas ◽  
Ruslan Akulenko ◽  
Ulla Ruffing ◽  
Mathias Herrmann ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Whole Blood ◽  
Blood Cells ◽  
White Blood Cells ◽  
Whole Blood Assay ◽  
Blood Assay

scholarly journals Management of clozapine treatment during the COVID-19 pandemic

2020 ◽  
Vol 10 ◽  
pp. 204512532092816 ◽  
Author(s):  
Siobhan Gee ◽  
Fiona Gaughran ◽  
James MacCabe ◽  
Sukhi Shergill ◽  
Eromona Whiskey ◽  
...  
Keyword(s):  
Healthcare Workers ◽  
Signs And Symptoms ◽  
Physical Contact ◽  
Full Blood Count ◽  
Risk Of Infection ◽  
Clozapine Treatment ◽  
Neutropenic Sepsis ◽  
Blood Assay ◽  
Blood Monitoring ◽  
Increased Risk

Clozapine is the only available treatment for refractory schizophrenia but its use involves frequent physical contact with healthcare workers for the purpose of mandatory blood monitoring. During the COVID-19 pandemic, patients taking clozapine will be self-isolating to reduce the risk of infection, not least because these patients are at high risk of serious illness and fatality because of high rates of diabetes, obesity and pulmonary disease and an increased risk of pneumonia. Problems may also arise because both clozapine-induced myocarditis and neutropenic sepsis share signs and symptoms with COVID-19 (fever, chest pain, dyspnoea, etc.). We recommend decreasing the frequency of physical contacts by extending the blood monitoring interval to 12 weeks in those patients taking clozapine for more than 1 year. To distinguish COVID-19 from clozapine-related physical adverse effects, we suggest an urgent antigen test alongside a full blood count. In those taking clozapine who develop COVID-19, we suggest continuing with clozapine whenever possible (even during ventilation), reducing the dose if necessary in line with blood assay results. Blood monitoring should continue but clozapine should only cease if there is a significant fall in neutrophils (COVID-19 is linked to lymphopenia but not neutropenia). To protect against the likelihood and severity of respiratory infection, we recommend the use of vitamin D in all clozapine patients. Initiation of clozapine is likely to remain problematic while the risk of infection remains, given the degree of physical contact required to assure safety.

Sign in / Sign up

Export Citation Format

Share Document